Payment overview · 2025
General Payments
$273.06
13 reported records · 8 companies
Healthcare provider profile · identity verified
Philip J Hess, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TULSA, OK · NPI 1750368924
Verified facts
What the public records show
CMS Open Payments records show Philip J Hess, M.D. received $273.06 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.06 | 24.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.29 | 23.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.62 | 17.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.85 | 8.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.12 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.90 | 6.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.85 | 6.5% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.37 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.06 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.67 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.67 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.39 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.39 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 97 |
| Lisinopril | Lisinopril | 307 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 62 |
| Losartan Potassium | Losartan Potassium | 200 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 37 |
| Gabapentin | Gabapentin | 153 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 38 |
| Eliquis | Apixaban | 120 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 47 |
| Furosemide | Furosemide | 112 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 38 |
| Omeprazole | Omeprazole | 112 | 38 |
| Metformin Hcl | Metformin Hcl | 103 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 34 |
| Potassium Chloride | Potassium Chloride | 97 | 34 |
| Carvedilol | Carvedilol | 92 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 30 |
| Alprazolam | Alprazolam | 84 | 25 |
| Allopurinol | Allopurinol | 81 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 26 |
| Glimepiride | Glimepiride | 78 | 25 |
| Sertraline Hcl | Sertraline Hcl | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 76 | 23 |
| Metformin Hcl Er | Metformin Hcl | 72 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 22 |
| Alendronate Sodium | Alendronate Sodium | 70 | 21 |
| Jardiance | Empagliflozin | 70 | 21 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 12 |
| Finasteride | Finasteride | 57 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 26 |
| Ondansetron Odt | Ondansetron | 50 | 18 |
| Simvastatin | Simvastatin | 49 | 15 |
| Atenolol | Atenolol | 48 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 16 |
| Terazosin Hcl | Terazosin Hcl | 41 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Ozempic | Semaglutide | 39 | 11 |
| Famotidine | Famotidine | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Meloxicam | Meloxicam | 38 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 14 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | 11 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Valium | Diazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.06 · 13 records | PFIZER INC. | ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, LYMPHA PRESS OPTIMAL PLUS(US) BT, MOUNJARO, NURTEC ODT, PCD-51 731A (US) - White, PCD-52 737A (US) White, QULIPTA, UBRELVY, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error